PaTHway Phase 3 Trial Analysis

Demographics and Baseline Characteristics Pathway Characteristics Age (years) (n) TransCon PTH (N = 61) Placebo (N = 21) Mean (SD) 61 49.0 (13.1) 21 47.3 (11.4) Age Group (years) - n (%) <50 28 (45.9) 14 (66.7) ≥50 33 (54.1) 7 (33.3) Sex at Birth n (%) Female 46 (75.4) 18 (85.7) Body Mass Index (kg/m²) (n) Mean (SD) Menopausal Status - n (%) Postmenopausal 61 27.3 (5.8) 46 21 29.5 (5.7) 18 19 (41.3) 3 (16.7) 10 Data on file, Ascendis Pharma 2022. TransCon PTH is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. ascendis pharma TRIAL

View entire presentation